Last Updated: 16 Sep 2024
Executive Summary
ICU Medical Inc. (ICUI) is a leading medical device company specializing in infusion therapy and critical care applications. With a market capitalization of $4.37 billion, the company has a strong financial position and is well-positioned for growth. Despite recent earnings challenges, analysts remain optimistic about ICUI's long-term prospects, with a median target price of $162.
Company Overview
ICU Medical develops, manufactures, and sells a wide range of medical devices used in hospitals, clinics, and other healthcare settings. The company's products include infusion pumps, IV sets, catheters, and other consumables. ICUI has a global presence with operations in over 100 countries.
Fundamental Analysis
Revenue: ICUI's revenue has grown steadily in recent years, reaching $2.3 billion in the trailing twelve months (TTM). The company's quarterly revenue growth of 0.086% year-over-year indicates a stable business.
Earnings: ICUI reported a loss per share (EPS) of -$2.92 in the TTM. This decline was primarily due to increased expenses and supply chain disruptions.
Profitability: ICUI's profit margins have been under pressure in recent quarters, with a negative profit margin of -0.0307% in the TTM.
Balance Sheet: ICUI has a strong balance sheet with a low debt-to-equity ratio and ample liquidity.
Technical Analysis
Price Action: ICUI's stock price has been volatile in recent months, trading between a 52-week high of $180.88 and a low of $78.28.
Moving Averages: The stock's 50-day moving average is currently at $143.53, while the 200-day moving average is at $111.83.
Support and Resistance: Key support levels for ICUI include $160 and $140, while resistance levels include $180 and $200.
Short Term Outlook
In the short term, ICUI's stock price is expected to remain volatile. Analysts are cautious about the company's ability to improve its profitability in the near future. However, the company's strong balance sheet and market position provide some support for the stock.
Long Term Outlook
Over the long term, analysts are more optimistic about ICUI's prospects. The company's focus on innovation and its global presence position it well for growth in the healthcare industry. Additionally, the increasing demand for medical devices in emerging markets is expected to benefit ICUI.
Analyst Recommendations
Of the analysts covering ICUI, 4 have a "Buy" rating, while 1 has a "Hold" rating. The median target price is $162, which represents a potential upside of 10.6% from the current price of $179.
